{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:28:07Z","timestamp":1789738087145,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Human Frontiers Science Program Research","award":["RGP0042\/2013"],"award-info":[{"award-number":["RGP0042\/2013"]}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["I-2082-20210327"],"award-info":[{"award-number":["I-2082-20210327"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI CCSG","award":["2P30CA142543-11"],"award-info":[{"award-number":["2P30CA142543-11"]}]},{"name":"NIH S10","award":["1S10OD026758-01"],"award-info":[{"award-number":["1S10OD026758-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03242-x","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:06:21Z","timestamp":1748937981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines"],"prefix":"10.1038","volume":"15","author":[{"given":"Fatma Neslihan","family":"Kalkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Sadik","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Ezgi","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Posner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdal","family":"Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"5","key":"3242_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett, A. K., Wetzler, M. & L\u00f6wenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29(5), 487\u2013494 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3242_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14740338.2016.1176139","volume":"15","author":"A Isidori","year":"2016","unstructured":"Isidori, A., Loscocco, F. & Visani, G. AML therapy in the elderly: A time for a change. Expert Opin. Drug Saf. 15, 891\u2013892 (2016).","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"3242_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41375-020-01058-4","volume":"35","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2021","unstructured":"Mart\u00ednez-Cuadr\u00f3n, D. et al. Evolving treatment patterns and outcomes in older patients (\u226560 years) with AML: Changing everything to change nothing?. Leukemia 35(6), 1571\u20131585. https:\/\/doi.org\/10.1038\/s41375-020-01058-4 (2021) (Epub 20201019).","journal-title":"Leukemia"},{"issue":"15","key":"3242_CR4","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein, M. S., Ershler, W. B., Jemal, A., Yates, J. W. & Baer, M. R. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer 119(15), 2720\u20132727. https:\/\/doi.org\/10.1002\/cncr.28129 (2013) (Epub 20130430).","journal-title":"Cancer"},{"issue":"4","key":"3242_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jgo.2015.04.002","volume":"6","author":"SMH Alibhai","year":"2015","unstructured":"Alibhai, S. M. H. et al. Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J. Geriatric Oncol. 6(4), 262\u2013271 (2015).","journal-title":"J. Geriatric Oncol."},{"key":"3242_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2016.12.001","volume":"53","author":"AD Heini","year":"2017","unstructured":"Heini, A. D. et al. Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. Leuk. Res. 53, 28\u201334 (2017).","journal-title":"Leuk. Res."},{"issue":"1","key":"3242_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/msb.2011.71","volume":"7","author":"M Cokol","year":"2011","unstructured":"Cokol, M. et al. Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7(1), 544. https:\/\/doi.org\/10.1038\/msb.2011.71 (2011).","journal-title":"Mol. Syst. Biol."},{"issue":"22","key":"3242_CR8","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/cancers13225722","volume":"13","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann, M., Schnetzke, U., Hochhaus, A. & Scholl, S. Management of acute myeloid leukemia: Current treatment options and future perspectives. Cancers 13(22), 5722 (2021).","journal-title":"Cancers"},{"key":"3242_CR9","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1182\/blood-2018-99-117287","volume":"132","author":"M Swaminathan","year":"2018","unstructured":"Swaminathan, M. et al. Clinical heterogeneity of AML is associated with mutational heterogeneity. Blood 132, 5240 (2018).","journal-title":"Blood"},{"issue":"6","key":"3242_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clml.2020.02.005","volume":"20","author":"A Burnett","year":"2020","unstructured":"Burnett, A. & Stone, R. AML: New drugs but new challenges. Clin. Lymphoma Myeloma Leuk. 20(6), 341\u2013350. https:\/\/doi.org\/10.1016\/j.clml.2020.02.005 (2020) (Epub 20200215).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"3242_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6), 722\u2013731. https:\/\/doi.org\/10.1182\/blood-2017-04-779405 (2017) (Epub 20170606).","journal-title":"Blood"},{"issue":"10","key":"3242_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.Cd-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6(10), 1106\u20131117. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0313 (2016) (Epub 20160812).","journal-title":"Cancer Discov."},{"issue":"6132","key":"3242_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1234769","volume":"340","author":"F Wang","year":"2013","unstructured":"Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340(6132), 622\u2013626. https:\/\/doi.org\/10.1126\/science.1234769 (2013) (Epub 20130404).","journal-title":"Science"},{"issue":"3","key":"3242_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26(3), 585\u2013615. https:\/\/doi.org\/10.1111\/j.1744-7348.1939.tb06990.x (1939).","journal-title":"Ann. Appl. Biol."},{"issue":"2","key":"3242_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 11(2), 41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3 (2021).","journal-title":"Blood Cancer J."},{"issue":"9","key":"3242_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","volume":"21","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M. et al. Acute myeloid leukemia: Historical perspective and progress in research and therapy over 5 decades. Clin. Lymphoma Myeloma Leuk. 21(9), 580\u2013597. https:\/\/doi.org\/10.1016\/j.clml.2021.05.016 (2021) (Epub 20210529).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"32","key":"3242_CR17","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1200\/jco.2008.20.6490","volume":"27","author":"F Mandelli","year":"2009","unstructured":"Mandelli, F. et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J. Clin. Oncol. 27(32), 5397\u20135403. https:\/\/doi.org\/10.1200\/jco.2008.20.6490 (2009) (Epub 20091013).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"3242_CR18","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41375-023-01972-3","volume":"37","author":"A Palau","year":"2023","unstructured":"Palau, A. et al. Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. Leukemia 37(9), 1830\u20131841. https:\/\/doi.org\/10.1038\/s41375-023-01972-3 (2023).","journal-title":"Leukemia"},{"issue":"7","key":"3242_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383(7), 617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"3242_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 135(24), 2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856 (2020).","journal-title":"Blood"},{"issue":"8","key":"3242_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo, C. D. et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am. J. Hematol. 97(8), 1035\u20131043. https:\/\/doi.org\/10.1002\/ajh.26601 (2022) (Epub 20220530).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"3242_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz, K. W. et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am. J. Hematol. 99(4), 615\u2013624. https:\/\/doi.org\/10.1002\/ajh.27246 (2024) (Epub 20240211).","journal-title":"Am. J. Hematol."},{"key":"3242_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.562558","volume":"10","author":"B Samra","year":"2020","unstructured":"Samra, B., Konopleva, M., Isidori, A., Daver, N. & DiNardo, C. Venetoclax-based combinations in acute myeloid leukemia: Current evidence and future directions. Front. Oncol. 10, 562558. https:\/\/doi.org\/10.3389\/fonc.2020.562558 (2020) (Epub 20201105).","journal-title":"Front. Oncol."},{"issue":"6","key":"3242_CR24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28(6), 1212\u20131223. https:\/\/doi.org\/10.1038\/s41591-022-01819-x (2022) (Epub 20220526).","journal-title":"Nat. Med."},{"issue":"Supplement 1","key":"3242_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood-2022-164922","volume":"140","author":"SP Desikan","year":"2022","unstructured":"Desikan, S. P. et al. Updated phase IIb results of venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia. Blood 140(Supplement 1), 534\u2013536. https:\/\/doi.org\/10.1182\/blood-2022-164922 (2022).","journal-title":"Blood"},{"key":"3242_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19519","author":"WY Jen","year":"2024","unstructured":"Jen, W. Y. et al. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.19519 (2024) (Epub 20240509).","journal-title":"Br. J. Haematol."},{"key":"3242_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35388","author":"J Senapati","year":"2024","unstructured":"Senapati, J. et al. Lower intensity therapy with cladribine\/low dose cytarabine\/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer https:\/\/doi.org\/10.1002\/cncr.35388 (2024) (Epub 20240529).","journal-title":"Cancer"},{"issue":"13","key":"3242_CR28","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein, E. M. et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study. Blood 137(13), 1792\u20131803. https:\/\/doi.org\/10.1182\/blood.2020007233 (2021).","journal-title":"Blood"},{"issue":"15_suppl","key":"3242_CR29","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2020.38.15_suppl.7501","volume":"38","author":"CD Dinardo","year":"2020","unstructured":"Dinardo, C. D. et al. Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). J. Clin. Oncol. 38(15_suppl), 7501. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7501 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"3242_CR30","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1007\/s00204-022-03359-2","volume":"96","author":"A Morell","year":"2022","unstructured":"Morell, A. et al. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Arch. Toxicol. 96(12), 3265\u20133277. https:\/\/doi.org\/10.1007\/s00204-022-03359-2 (2022) (Epub 20220816).","journal-title":"Arch. Toxicol."},{"issue":"12","key":"3242_CR31","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea, D. A. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 24(12), 1859\u20131866. https:\/\/doi.org\/10.1038\/s41591-018-0233-1 (2018) (Epub 20181112).","journal-title":"Nat. Med."},{"issue":"10","key":"3242_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.25929","volume":"95","author":"I Aldoss","year":"2020","unstructured":"Aldoss, I. et al. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am. J. Hematol. 95(10), 1193\u20131199. https:\/\/doi.org\/10.1002\/ajh.25929 (2020) (Epub 20200728).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"3242_CR33","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali, R. et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 106(4), 1034\u20131046. https:\/\/doi.org\/10.3324\/haematol.2019.244020 (2021) (Epub 20210401).","journal-title":"Haematologica"},{"issue":"23","key":"3242_CR34","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374(23), 2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"3242_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553\u2013567. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015 (2010) (Epub 20101209).","journal-title":"Cancer Cell"},{"issue":"7390","key":"3242_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390), 474\u2013478. https:\/\/doi.org\/10.1038\/nature10860 (2012) (Epub 20120215).","journal-title":"Nature"},{"issue":"4","key":"3242_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14728222.2021.1915991","volume":"25","author":"F Gonzales","year":"2021","unstructured":"Gonzales, F. et al. Targeting RUNX1 in acute myeloid leukemia: Preclinical innovations and therapeutic implications. Expert Opin. Ther. Targets. 25(4), 299\u2013309. https:\/\/doi.org\/10.1080\/14728222.2021.1915991 (2021) (Epub 20210428).","journal-title":"Expert Opin. Ther. Targets."},{"issue":"3","key":"3242_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12(3), 329\u2013341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013 (2013) (Epub 20130117).","journal-title":"Cell Stem Cell"},{"issue":"3","key":"3242_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4(3), 362\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609 (2014) (Epub 20131217).","journal-title":"Cancer Discov."},{"key":"3242_CR40","doi-asserted-by":"publisher","first-page":"9312971","DOI":"10.1155\/2022\/9312971","volume":"2022","author":"X Tian","year":"2022","unstructured":"Tian, X. et al. Inhibition of DEK enhances doxorubicin-induced apoptosis and cell cycle arrest in T-cell acute lymphoblastic leukemia cells. Dis. Markers. 2022, 9312971. https:\/\/doi.org\/10.1155\/2022\/9312971 (2022) (Epub 20220620).","journal-title":"Dis. Markers."},{"issue":"1","key":"3242_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","volume":"15","author":"TE Lew","year":"2022","unstructured":"Lew, T. E. & Seymour, J. F. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: Lessons from monotherapy and chemotherapy combination. J. Hematol. Oncol. 15(1), 75. https:\/\/doi.org\/10.1186\/s13045-022-01295-3 (2022) (Epub 20220603).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"3242_CR42","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11(1), 5327. https:\/\/doi.org\/10.1038\/s41467-020-19119-8 (2020) (Epub 20201021).","journal-title":"Nat. Commun."},{"issue":"5","key":"3242_CR43","first-page":"1315","volume":"4","author":"JF Ju","year":"1998","unstructured":"Ju, J. F. et al. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin. Cancer Res. 4(5), 1315\u20131322 (1998).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"3242_CR44","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10(4), 536\u2013551. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710 (2020) (Epub 20200123).","journal-title":"Cancer Discov."},{"issue":"2","key":"3242_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/leu.2017.243","volume":"32","author":"TC Teh","year":"2018","unstructured":"Teh, T. C. et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 32(2), 303\u2013312. https:\/\/doi.org\/10.1038\/leu.2017.243 (2018) (Epub 20170728).","journal-title":"Leukemia"},{"issue":"5","key":"3242_CR46","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/s0006-291x(02)02043-0","volume":"296","author":"KH Lee","year":"2002","unstructured":"Lee, K. H. et al. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. Biochem. Biophys. Res. Commun. 296(5), 1125\u20131133. https:\/\/doi.org\/10.1016\/s0006-291x(02)02043-0 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"3242_CR47","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1038\/srep05577","volume":"4","author":"S-M Liu","year":"2014","unstructured":"Liu, S.-M., Chen, W. & Wang, J. Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. Sci. Rep. 4(1), 5577. https:\/\/doi.org\/10.1038\/srep05577 (2014).","journal-title":"Sci. Rep."},{"issue":"1","key":"3242_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1208\/s12248-010-9246-5","volume":"13","author":"P Chen","year":"2011","unstructured":"Chen, P. et al. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells. AAPS J. 13(1), 131\u2013140. https:\/\/doi.org\/10.1208\/s12248-010-9246-5 (2011) (Epub 20101230).","journal-title":"AAPS J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03242-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T08:58:41Z","timestamp":1758185921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03242-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03242-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.23.581821","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article Fatma Neslihan Kalkan and Muhammed Sadik Yildiz were omitted as equally contributing authors. The statement has now been added and reads: \u201cThese authors contributed equally: Fatma Neslihan Kalkan and Muhammed Sadik Yildiz.\u201d","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.T. is a co-founder of BAIT-BIO LLC and a scientific advisory board member for BLASTID Inc. At the time of this publication N.E.W. is employee of Bristol Myers Squibb. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19431"}}